Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Vecabrutinib |
| Synonyms | |
| Therapy Description |
Vecabrutinib (SNS-062) inhibits BTK, including BTK mutations associated with inhibitor resistance, which potentially results in decreased tumor growth (Mol Cancer Ther December 1 2015 (14) (12 Supplement 2) C186). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Vecabrutinib | SNS-062|BSK-4841|BIIB-062|BIIB062 | BTK inhibitor 38 | Vecabrutinib (SNS-062) inhibits BTK, including BTK mutations associated with inhibitor resistance, which potentially results in decreased tumor growth (Mol Cancer Ther December 1 2015 (14) (12 Supplement 2) C186). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03037645 | Phase Ib/II | Vecabrutinib | Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers | Terminated | USA | 0 |